Open access

1396 TriTCE CPI: a novel trispecifc T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors
Meghan M Verstraete, Maya Poffenberger, Matteo Zago, Veronica Luu, Brenda Ma, Nichole Escalante, Janessa Li, Diego Perez Escanda, Siran Cao, Edward Meier, Sifa Arrafi, Yun Peng, Anna Von Rossum, Genevieve Desjardins, Nina Weisser, Thomas Spreter von Kreudenstein

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1551; DOI: 10.1136/jitc-2023-SITC2023.1396
1397 CDR404, an antibody-based bispecific & bivalent T-cell engager targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)
Melissa Vrohlings, Stephanie Jungmichel, Ivana Tosevski, Alessio Vantellini, Philip Knobel, Nadia Sanchez, Elizabeth Ross, Marian Van Kerckhoven, Giorgia Giacomazzi, Maria Liivrand, Reija Hieta, Nicholas Dupuis, Dieter Rondas, Pamela Swatkowski, Daniel Lenherr-Frey, Swethajit Biswas, Gilberto Lopes, Leonardo Borras

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1552; DOI: 10.1136/jitc-2023-SITC2023.1397
1398 Immune responses and long-term survival with mRNA vaccine targeting diffuse midline glioma
Frances Weidert, Christina Von Roemeling, James McGuiness, Jonathan Chardon-Robles, Nagheme Thomas, Anna Devries, Sadeem Qdaisat, Dingpeng Zhang, Adam Grippin, Aida Karachi, Jianping Huang, Maryam Rahman, Elizabeth Ogando-Rivas, Paul Castillo, Eugene Hwang, Hector Mendez-Gomez, Study Staff, Natalie Silver, John A Ligon, Elias Sayour

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1553; DOI: 10.1136/jitc-2023-SITC2023.1398
1399 Identification of alternative splicing-derived targets for TCR-T cell therapies
Elise C Wilcox, Alex Chen, Chenwei Lin, Lisa A Jones, Philip R Gafken, Roland K Strong, Stanley C Lee, Aude Chapuis

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1554-A1556; DOI: 10.1136/jitc-2023-SITC2023.1399
1400 YF550-C1 promotes T cell activation, cytokines release and induces robust tumor growth inhibition in syngeneic and PDX tumor models
Jie Ye, Tengfei Liu, Yahui Liu, Xueqiang Liu, Fan Wu, Yushuang Chai, Xingyu Lin, Tingting Lu, Na An, Steven Cha, Xuebin Liao

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1557-A1558; DOI: 10.1136/jitc-2023-SITC2023.1400
1401 PLT012, a monoclonal antibody targeting CD36, unleashes anti-tumor immunity via metabolic reprogramming in tumor microenvironment
Yi-Ru Yu, Chin-Hsien Tsai, Huey-Wen Hsiao, Jaeoh Park, Pandelakis Koni, Hung-Kai Chen, Lana Kandalaft, Claudia Lengerke

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1559; DOI: 10.1136/jitc-2023-SITC2023.1401
1403 A bispecific antibody targeting PD1 and CD40 displays potent anti-tumor efficacy through two mechanisms: PD1 blockade and PD1-dependent CD40 agonism
Zhenqing Zhang, Yunli Jia, Weifeng Huang, Chao Wang, Wenchao Jiang, Zhiyuan Li, Andy Tsun

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1561; DOI: 10.1136/jitc-2023-SITC2023.1403
1404 MONTANIDE™ ISA 51 VG: open access adjuvant dedicated to therapeutic vaccines
Marie-Eve Koziol

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1562; DOI: 10.1136/jitc-2023-SITC2023.1404
1405 Comparative analysis of complete blood count, serum chemistry and immune phenotype between SRG and CD rats
Koh Meng Aw Yong, Christoph Eberle, Christopher Dowdy, Chris Brenzel, Diane Begemann, Grace Walton, Fallon Noto, Stephen Festin

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1563; DOI: 10.1136/jitc-2023-SITC2023.1405
1406 A novel PTK7-directed antibody-drug conjugate (ADC) PRO1107 demonstrated broad antitumor activity with a promising safety profile in preclinical models
Yang Xiao, Lei Wang, Haidong Liu, Wanwan Shen, Lin Zhang, Tae Han, Baiteng Zhao, Zhu Chen

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1564; DOI: 10.1136/jitc-2023-SITC2023.1406

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages